Positive data from two Phase 2 studies of filgotinib, a Janus kinase 1 inhibitor being developed for several inflammatory conditions, were published online on 22 October 2018 in The Lancet, Gilead Sciences Inc and Galapagos NV announced.
The first trial, called EQUATOR, is in patients with psoriatic arthritis. The second, TORTUGA, is in patients with ankylosing spondylitis, a form of arthritis that primarily affects the spine.